NECTIN4 and cancer: The identification of biomarkers to predict response to targeted therapies is crucial to improve the management of patients with cancer.32 Here, we provide data from a multicenter mUC patient cohort highlighting NECTIN4 amplifications as genomic biomarkers to predict EV responses and favorable outcomes.